Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.
Bettelli S, Marcheselli R, Pozzi S, Marcheselli L, Papotti R, Forti E, Cox MCC, Di Napoli A, Tadmor T, Mansueto GR, Musto P, Flenghi L, Quintini M, Galimberti S, Lalinga V, Donati V, Maiorana A, Polliack A, Sacchi S.
Bettelli S, et al. Among authors: lalinga v.
Leuk Res. 2021 May;104:106552. doi: 10.1016/j.leukres.2021.106552. Epub 2021 Feb 27.
Leuk Res. 2021.
PMID: 33689920
No abstract available.